Prostate cancer pill launches in UK

In the UK, there has been a recent launch of a life-prolonging prostate cancer pill but NHS patients have not got an access to it yet.

Men with advanced prostate cancer have been benefitted with Abiraterone acetate, marketed under the trade name Zytiga as their lives have been extended.

About 14 days ago, it received a European Union licence, and this has made it a legal medicine in the UK, but actually only patients have been able to access it yet.

Generation of testosterone in all tissues, including cancer tumors are blocked by the drug. Prostate cancer grows and spreads with the male sex hormone.

There was a phase III trial conducted on about 2,000 men who were in the advanced stages of cancer. There was an extension in the lives of men who took the drug by 15.8 months on average than men who took a placebo.

British researchers at the Institute of Cancer Research (ICR) and the Royal Marsden Hospital have developed Abiraterone.

Professor Alan Ashworth, chief executive of the ICR in London, said, “This drug will make a significant impact on the treatment of men suffering advanced prostate cancer.”